TABLE 1.
RNA m6A modification, targets, and drugs in clinical trials.
| Target | Inhibitor | Mechanism | Cancer type | Clinical trial | Phase | Status | References |
|---|---|---|---|---|---|---|---|
| METTL3 | STC‐15 | Inhibiting the catalytic activity of METTL3 | Acute myeloid leukemia | NCT05584111 | I | Recruiting | N/A |
| STM2457 | Competitive binding to the binding site of the SAM | myeloid leukemia | N/A | N/A | N/A | 120 | |
| FTO | Entacapone | Regulating the FTO–FOXO1 signaling pathway | Gastrointestinal stromal tumor | NCT04006769 | I | Recruiting | 121 |
| R‐2HG | Activating expression of RARA | Leukemia | N/A | N/A | N/A | 122 | |
| FB23‐2 | Activating expression of ASB2 | Leukemia | N/A | N/A | N/A | 123 | |
| Saikosaponin‐D | Increasing global m6A RNA methylation | Leukemia | N/A | N/A | N/A | 124 | |
| CS1/CS2 | Inhibiting expression of immune checkpoint genes | Leukemia | N/A | N/A | N/A | 125 | |
| Dac51 | Blocking immune evasion | Lung cancer and melanoma | N/A | N/A | N/A | 126 | |
| ALKBH5 | ALK‐04 | Reducing m6A levels, abnormal splicing, Mct4/Slc16a3 expression, and lactate level | Melanoma | N/A | N/A | N/A | 127 |
| IGF2BP2/3 | CWI1‐2 | Inhibiting glutamine metabolism regulated by MYC, GPT2, and SLC1A5 | Acute myeloid leukemia | N/A | N/A | N/A | 128 |